CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM | N206829 | CUBIST PHARMACEUTICALS LLC
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 7129232 | May 15, 2028PED: Nov 15, 2028 | PED | Yes | Yes | — | |
| 8906898 | May 28, 2034PED: Nov 28, 2034 | PED | Yes | Yes | — | — |
| 8968753 | Mar 14, 2034PED: Sep 14, 2034 | PED | — | — | — | |
| 9320740 | Mar 14, 2034PED: Sep 14, 2034 | PED | — | Yes | — | — |
| 9724353 | Sep 7, 2032PED: Mar 7, 2033 | PED | — | — | — | |
| 9872906 | Mar 14, 2034PED: Sep 14, 2034 | PED | — | Yes | — | — |
| 10028963 | Sep 7, 2032PED: Mar 7, 2033 | PED | — | — | — | |
| 10125149 | Aug 14, 2035PED: Feb 14, 2036 | PED | — | Yes | — | — |
| 10376496 | Sep 9, 2034PED: Mar 9, 2035 | PED | — | — | — | |
| 10420841 | Mar 14, 2034PED: Sep 14, 2034 | PED | — | — | — | |
| 10933053 | Sep 9, 2034PED: Mar 9, 2035 | PED | — | — | — | |
| 11278622 | Mar 14, 2034PED: Sep 14, 2034 | PED | — | — | — |
Cubist Pharmaceuticals added U.S. Patent 10,420,841 to the Orange Book for Zerbaxa (ceftolozane sulfate; tazobactam sodium), NDA 206829.
New: New record
ZERBAXA (ceftolozane sulfate/tazobactam sodium) lists U.S. Patent 11,278,622 in the Orange Book, extending patent protection through its listed expiration date.
New: New record
Cubist Pharmaceuticals added U.S. Patent 7,129,232 (pediatric exclusivity designation) to the Orange Book listing for Zerbaxa (ceftolozane sulfate; tazobactam sodium).
New: New record
Cubist Pharmaceuticals added U.S. Patent 9,724,353 to the Orange Book for Zerbaxa (ceftolozane sulfate; tazobactam sodium), listing a pediatric exclusivity extension.
New: New record
Cubist Pharmaceuticals added patent 9,872,906 (pediatric exclusivity designation noted) to the Orange Book listing for Zerbaxa (ceftolozane sulfate; tazobactam sodium) under NDA 206829.
New: New record
Cubist Pharmaceuticals added U.S. Patent 10,125,149 to the Orange Book for Zerbaxa (ceftolozane sulfate; tazobactam sodium), NDA 206829.
New: New record
Cubist Pharmaceuticals added U.S. Patent 10,376,496 to the Orange Book for Zerbaxa (ceftolozane sulfate/tazobactam sodium), with a pediatric exclusivity extension period noted.
New: New record
Cubist Pharmaceuticals added U.S. Patent 10,028,963 to the Orange Book for Zerbaxa (ceftolozane sulfate; tazobactam sodium), extending patent protection for the combination antibiotic.
New: New record
Cubist Pharmaceuticals added U.S. Patent 10,933,053 (pediatric exclusivity designation) to the Orange Book listing for Zerbaxa (ceftolozane sulfate; tazobactam sodium) under NDA 206829.
New: New record
Cubist Pharmaceuticals added U.S. Patent 9,320,740 (pediatric exclusivity voucher designation) to the Orange Book for Zerbaxa (ceftolozane sulfate; tazobactam sodium) under NDA 206829.
New: New record
Cubist Pharmaceuticals added U.S. Patent 8,906,898 (with pediatric exclusivity designation) to the Orange Book for Zerbaxa (ceftolozane sulfate; tazobactam sodium).
New: New record
Cubist Pharmaceuticals listed U.S. Patent 8,968,753 (pediatric exclusivity designee patent) in the Orange Book for Zerbaxa (ceftolozane sulfate/tazobactam sodium).
New: New record